

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8164681

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the ASSIGNEE NAME FROM TISENTO THERAPEUTICS, INC. TO TISENTO THERAPEUTICS INC. previously recorded on Reel 064792 Frame 0500. Assignor(s) hereby confirms the ASSIGNMENT.

CONVEYING PARTY DATA

Name	Execution Date
CYCLERION THERAPEUTICS, INC.	07/28/2023

RECEIVING PARTY DATA

Name:	TISENTO THERAPEUTICS INC.
Street Address:	245 FIRST STREET, RIVERVIEW II, 18TH FLOOR
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142

PROPERTY NUMBERS Total: 52

Property Type	Number
Patent Number:	11466014
Patent Number:	10472363
Patent Number:	10858363
Patent Number:	11731977
Patent Number:	11690828
Patent Number:	11466015
Application Number:	15693758
Application Number:	16273557
Application Number:	16348359
Application Number:	16976249
Application Number:	16976430
Application Number:	17112351
Application Number:	17258913
Application Number:	17485892
Application Number:	17913273
Application Number:	17954713
Application Number:	17954725
Application Number:	18031371

PATENT

Property Type	Number
Application Number:	18196826
Application Number:	18212948
Application Number:	62382942
Application Number:	62419059
Application Number:	62423445
Application Number:	62468598
Application Number:	62482486
Application Number:	62639642
Application Number:	62639846
Application Number:	62696582
Application Number:	62697671
Application Number:	63000040
Application Number:	63090849
Application Number:	63135797
Application Number:	63177020
Application Number:	63177023
Application Number:	63229248
Application Number:	63229251
Application Number:	63350708
Application Number:	63392643
Application Number:	63410829
Application Number:	63417120
Application Number:	63417180
PCT Number:	US2019021076
PCT Number:	US2017049834
PCT Number:	US2017060299
PCT Number:	US2019021080
PCT Number:	US2019041437
PCT Number:	US2021024189
PCT Number:	US2021054632
PCT Number:	US2022025310
PCT Number:	US2022025308
PCT Number:	US2023024932
PCT Number:	US2023028709

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6174496580
Email: eshea@mccarter.com
Correspondent Name: MCCARTER & ENGLISH LLP
Address Line 1: 265 FRANKLIN STREET
Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	138914-00001
--------------------------------	--------------

NAME OF SUBMITTER:	JAMES ALBURGER
---------------------------	----------------

SIGNATURE:	/James Alburger/
-------------------	------------------

DATE SIGNED:	09/13/2023
---------------------	------------

Total Attachments: 12

source=BULK Assignment w Assignment Cover Sheet for Filing#page1.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page2.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page3.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page4.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page5.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page6.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page7.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page8.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page9.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page10.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page11.tif
source=BULK Assignment w Assignment Cover Sheet for Filing#page12.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CYCLERION THERAPEUTICS, INC.	07/27/2023
RECEIVING PARTY DATA	
Company Name:	TISENTO THERAPEUTICS, INC.
Street Address:	245 FIRST STREET, RIVERVIEW II, 18TH FLOOR
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142
PROPERTY NUMBERS Total: 46	
Property Type	Number
Patent Number:	10472363
Patent Number:	10858363
Patent Number:	11466015
Patent Number:	11466014
Application Number:	63000040
Application Number:	17913273
Application Number:	63090849
Application Number:	63135797
Application Number:	18031371
Application Number:	63177020
Application Number:	63229248
Application Number:	63177023
Application Number:	63229251
Application Number:	63392643
Application Number:	63417180
Application Number:	63350708
Application Number:	63410829

Application Number:	63417120
Application Number:	62382942
Application Number:	62423445
Application Number:	62468598
Application Number:	62482486
Application Number:	17112351
Application Number:	17485892
Application Number:	18212948
Application Number:	62419059
Application Number:	16348359
Application Number:	18196826
Application Number:	62639846
Application Number:	17954713
Application Number:	62639642
Application Number:	17954725
Application Number:	62696582
Application Number:	62697671
Application Number:	17258913
PCT Number:	US2021024189
PCT Number:	US2021054632
PCT Number:	US2022025310
PCT Number:	US2022025308
PCT Number:	US2023028709
PCT Number:	US2023024932
PCT Number:	US2017049834
PCT Number:	US2017060299
PCT Number:	US2019021080
PCT Number:	US2019021076
PCT Number:	US2019041437

CORRESPONDENCE DATA

Fax Number: (617)607-9200
Phone: 6174496500
Email: cgiordani@mccarter.com
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Correspondent Name: XIN ZHANG
Address Line 1: 265 FRANKLIN STREET
Address Line 2: MCCARTER ENGLISH LLP
Address Line 4: BOSTON, MASSACHUSETTS 02110

NAME OF SUBMITTER:

XIN ZHANG

PATENT**REEL: 064889 FRAME: 0463**

Signature:	/Xin Zhang/
Date:	09/01/2023
Total Attachments: 9 source=138914_Assign_Cyclerion_to_Tisento_US_PCT#page1.tif source=138914_Assign_Cyclerion_to_Tisento_US_PCT#page2.tif source=138914_Assign_Cyclerion_to_Tisento_US_PCT#page3.tif source=138914_Assign_Cyclerion_to_Tisento_US_PCT#page4.tif source=138914_Assign_Cyclerion_to_Tisento_US_PCT#page5.tif source=138914_Assign_Cyclerion_to_Tisento_US_PCT#page6.tif source=138914_Assign_Cyclerion_to_Tisento_US_PCT#page7.tif source=138914_Assign_Cyclerion_to_Tisento_US_PCT#page8.tif source=138914_Assign_Cyclerion_to_Tisento_US_PCT#page9.tif	
RECEIPT INFORMATION EPAS ID: PAT8145230 Receipt Date: 09/01/2023	

PATENT ASSIGNMENT

This Patent Assignment dated as of July 28, 2023 (this “**Patent Assignment**”) is made by Cycleron Therapeutics, Inc., a Massachusetts corporation (“**Assignor**”), in favor of Tisento Therapeutics Inc. (formerly known as JW Cycle Inc.), a Delaware corporation (“**Assignee**”). Capitalized terms used but not defined in this Patent Assignment have the meanings ascribed to them in the Asset Purchase Agreement dated as of May 11, 2023 (the “**Purchase Agreement**”) among Assignee and Assignor.

Assignor and Assignee desire to execute this Patent Assignment for purposes of recording the assignment of the Assigned Patents (as defined below) and filing this Patent Assignment with the United States Patent and Trademark Office or any other applicable intellectual property offices or similar agencies outside of the United States, as may be necessary to effectuate the assignment of the Assigned Patents.

In consideration of the premises contained in the Purchase Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. Assignor hereby sells, conveys, transfers, assigns, and delivers to Assignee, its successors and assigns, all of Assignors’ rights, title, and interests throughout the world (including all divisions, continuations, continuations in part, reissues, extensions, reexaminations, certifications, revivals, renewals, and registrations or similar protective rights and applicable thereof) in and to (a) the Patents (and any and all registrations and applications therefor) listed on Attachment 1 and all goodwill corresponding thereto (collectively, the “**Assigned Patents**”) and (b) (i) all rights pertaining to the Assigned Patents and the inventions disclosed therein throughout the world or arising under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or otherwise; (ii) the right and power to assert, defend, and recover title to the Assigned Patents; (iii) all rights to assert causes of action (whether in law or equity), defend, sue, counterclaim, or recover damages for any past, present, and future infringement, misuse, misappropriation, impairment, unauthorized use, or other violation of any rights in or to the Assigned Patents; (iv) all proceeds, income, royalties, damages, and payments now or hereafter due or payable under or in respect of the Assigned Patents; and (v) all administrative rights arising from the Assigned Patents, including the right to prosecute applications and oppose, interfere with, or challenge the applications of others, the rights to claim priority to and from the Assigned Patents, including all rights of priority under the International Convention for the Protection of Industrial Property, and the rights to obtain renewals, continuations, divisions, and extensions of legal protection pertaining to the Assigned Patents.

2. Assignor further agrees, for itself and its executors and administrators, to cooperate with Assignee to enable Assignee to enjoy to the fullest extent the rights, title, and interests herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. From time to time, as and when requested by Assignee, Assignor shall execute and deliver, or cause to be executed and delivered, all such documents and instruments and shall take, or cause to be taken, all such further or other actions as are reasonably necessary to secure fully the Assigned Patents and rights, title, and interests herein confirmed or declared, or sold, assigned, transferred and conveyed to Assignee, its successors, assignees, and legal representatives, at Assignee’s expense and charges, including the filing and prosecution of any of the patent applications included in the Assigned Patents, the filing and prosecution of applications for patents in foreign countries, the filing and prosecution of substitution, reissue, divisional, continuation, or additional applications covering the inventions, execution of petitions, oaths, specifications, declarations, or other papers, the prompt production of pertinent facts and documents, the giving of testimony, preliminary statements, other statements, or other assistance in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved, including reissues and reexaminations, opposition proceedings, cancellation proceedings, priority

contests, public use proceedings, infringement actions and court actions, by communicating to Assignee, at Assignee's request, all facts known to Assignor relating to the inventions and their history, and by otherwise providing such reasonable assistance to aid Assignee in securing and maintaining proper patent protection for the inventions, including any aid required to perfect Assignee's title to all patents and patent applications under this Assignment.

3. Assignor hereby authorizes Assignee or its attorneys or agents to insert or correct any serial number(s), filing date(s), and/or other information for any of the Assigned Patents in this Patent Assignment, if appropriate.

4. Assignor authorizes the United States Patent and Trademark Office, and any official of any country or countries foreign to the United States whose duty it is to receive or register patents or applications or other evidence or forms of industrial property protection therefor, to record Assignee as the owner of the Assigned Patents and to issue all registrations for the Assigned Patents in the name of Assignee, its successors, assigns, and legal representatives, for the sole use of said Assignee, its successors, assigns, and legal representatives.

5. This Patent Assignment may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and will become effective when one or more counterparts have been signed by a party and delivered to the other parties. Copies of executed counterparts transmitted by fax or email shall be considered original executed counterparts for purposes of this Section, provided that receipt of copies of such counterparts is confirmed.

6. The Patent Assignment may not be amended, changed or modified in any fashion except by written instrument signed by Assignee and Assignor.

7. This Patent Assignment is subject in all respects to the terms and conditions of the Purchase Agreement. Nothing contained in this Patent Assignment shall be deemed to supersede, enlarge, modify, or waive any of the representations, warranties, covenants or other agreements contained in the Purchase Agreement. To the extent any provision of this Patent Assignment conflicts with the Purchase Agreement, the provisions of the Purchase Agreement shall control.

8. This Patent Assignment shall be binding upon and enforceable against Assignor and its successors and permitted assigns, and shall be binding upon, inure to the benefit of, and be enforceable by Assignee and its successors and permitted assigns.

[The next page is the signature page.]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Patent Assignment to be executed as of the date first written above.


ASSIGNOR:

CYCLERION THERAPEUTICS, INC.

By: Anjeza Gjino
Name: Anjeza Gjino
Title: Chief Financial Officer

CERTIFICATE OF ACKNOWLEDGEMENT

On this 27th day of July, 2023 before me appeared Anjeza Gjino personally known to me or proved to me on the basis of satisfactory evidence to me known to be the person who signed the foregoing instrument and who, being duly sworn by me, did depose and state that: s/he resides at 119 Beacon St. Apt 3, Boston, MA 02116; that s/he is the Chief Financial Officer of Assignor, the corporation described in and which executed the above instrument; that s/he signed the instrument in the name of Assignor; and that s/he had the authority to sign the instrument on behalf of Assignor.



Commonwealth of: Virginia County of: Prince William

Notarized online using audio-video communication

Judith Moore
Notary Public
Notary Registration Number: 8030982
My Commission Expires: 10/31/2026


[Signature page to Patent Assignment]

PATENT
REEL: 064889 FRAME: 0467

ACKNOWLEDGED AND AGREED:

ASSIGNEE:

TISENTO THERAPEUTICS INC.

By: 
 DocuSigned by: 4F280783282CF498...
 Name: Alton Lo
 Title: Secretary and Treasurer

[Signature Page to Patent Assignment]

PATENT
REEL: 064889 FRAME: 0468

ATTACHMENT 1

M&E- CaseNumber	Cyclotron docket number	Title	Country	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date
127553-06301	CYC219P1	DEUTERATED sGC STIMULATORS	United States of America	63/000040	3/26/2020				
127553-06320	CYC219PCT1	DEUTERATED sGC STIMULATORS	Patent Cooperation Treaty	PCT/US2021/024189	3/25/2021	WO 2021/195403	9/30/2021		
127553-06302	CYC219PCT1US1	DEUTERATED sGC STIMULATORS	United States of America	17/913273	9/21/2022				
127553-06501	CYC224P1	TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR	United States of America	63/090849	10/13/2020				
127553-06502	CYC224P2	TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR	United States of America	63/135797	1/11/2021				
127553-06520	CYC224PCT1	TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR	Patent Cooperation Treaty	PCT/US2021/054632	10/12/2021	WO 2022/081610	4/21/2022		
127553-06503	CYC224PCT1US1	TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR	United States of America	18/031371	4/12/2023				
127553-06601	CYC226P1	SGC STIMULATORS	United States of America	63/177020	4/20/2021				
127553-06602	CYC226P2	SGC STIMULATORS	United States of America	63/229248	8/4/2021				
127553-06620	CYC226PCT1	SGC STIMULATORS	Patent Cooperation Treaty	PCT/US2022/025310	4/19/2022	WO 2022/225903	10/27/2022		

127553-06701	CYC227P1	TREATMENT OF CNS DISEASES WITH SGC STIMULATORS	United States of America	63/177023	4/20/2021				
127553-06702	CYC227P2	TREATMENT OF CNS DISEASES WITH SGC STIMULATORS	United States of America	63/29251	8/4/2021				
127553-06720	CYC227PCT1	TREATMENT OF CNS DISEASES WITH SGC STIMULATORS	Patent Cooperation Treaty	PCT/US2022/025308	4/19/2022	WO 2022/225902	10/27/2022		
127553-07001	CYC230P1	TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) WITH A CNS-PENETRANT SGC STIMULATOR IN COMBINATION WITH ANTIPSYCHOTICS	United States of America	63/392643	7/27/2022				
127553-07020	CYC230PCT1	TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) WITH A CNS-PENETRANT SGC STIMULATOR IN COMBINATION WITH ANTIPSYCHOTICS	Patent Cooperation Treaty	PCT/US2023/028709	7/26/2023				
127553-07101	CYC231P1	SGC STIMULATORS	United States of America	63/417180	10/18/2022				
127553-06901	CYC232P1	TREATMENT OF MITOCHONDRIAL DISEASES WITH A CNS-PENETRANT SGC STIMULATOR	United States of America	63/350708	6/9/2022				
127553-06902	CYC232P2	TREATMENT OF MITOCHONDRIAL DISEASES WITH A	United States of America	63/410829	9/28/2022				

		CNS-PENETRANT sGC STIMULATOR						
127553-06920	CYC232PCT1	TREATMENT OF MITOCHONDRIAL DISEASES WITH A CNS-PENETRANT SGC STIMULATOR	Patent Cooperation Treaty	PCT/US2023/24932	09-Jun-2023			
127553-07201	CYC233P1	TREATMENT OF MITOCHONDRIAL DISEASES WITH SGC STIMULATORS	United States of America	63/417120	10/18/2022			
127553-01501	IW172P1	SGC STIMULATORS	United States of America	62/382942	9/2/2016			
127553-01502	IW172P2	SGC STIMULATORS	United States of America	62/423445	11/17/2016			
127553-01503	IW172P3	SGC STIMULATORS	United States of America	62/468598	3/8/2017			
127553-01504	IW172P4	SGC STIMULATORS	United States of America	62/482486	4/6/2017			
127553-01520	IW172PCT1	FUSED BICYCLIC SGC STIMULATORS	Patent Cooperation Treaty	PCT/US2017/049634	9/1/2017	WO2018/045276	3/8/2018	
127553-01505	IW172US1	SGC STIMULATORS	United States of America	15/693758	9/1/2017	US-2018-0065971-A1	3/8/2018	10472363
127553-01506	IW172US1CON1	SGC STIMULATORS	United States of America	16/273557	2/12/2019	US-2019-0248794-A1	8/15/2019	10858363
127553-01507	IW172US1CON2	SGC STIMULATORS	United States of America	17/112351	12/4/2020	US-2021-0087198-A1	3/25/2021	
127553-01508	IW172US1CON3	SGC STIMULATORS	United States of America	17/485892	9/27/2021	US-2022-0009937-A1	1/13/2022	
127553-01509	IW172US1CON4	SGC STIMULATORS	United States of America	18/212948	6/22/2023			
127553-04301	IW176P1	TREATMENT OF CNS DISEASES WITH SGC STIMULATORS	United States of America	62/419059	11/8/2016			
127553-04320	IW176PCT1	TREATMENT OF CNS DISEASES WITH sGC STIMULATORS	Patent Cooperation Treaty	PCT/US2017/060299	11/7/2017	WO 2018/089328	5/17/2018	

127553-04302	IW176PCT1US1	TREATMENT OF CNS DISEASES WITH sGC STIMULATORS	United States of America	16/348359	5/8/2019	US-2019-0343813-A1	11/14/2019		
127553-04303	IW176PCT1US1CON1	TREATMENT OF CNS DISEASES WITH sGC STIMULATORS	United States of America	18/196826	12-May-2023				
127553-05201	IW202P1	CRYSTALLINE FORMS OF AN sGC STIMULATOR	United States of America	62/639846	3/7/2018				
127553-05220	IW202PCT1	CRYSTALLINE FORMS OF AN sGC STIMULATOR	Patent Cooperation Treaty	PCT/US2019/021080	3/7/2019	WO 2019/173551	9/12/2019		
127553-05202	IW202PCT1US1	CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2- <i>a</i>]PYRAZINE AS sGC STIMULATORS	United States of America	16/976430	8/27/2020	US-2021-0115050-A1	4/22/2021	11466015	10/11/2022
127553-05203	IW202PCT1US1CON1	CRYSTALLINE FORMS OF AN sGC STIMULATOR	United States of America	17/954713	9/28/2022	US-2023-0095799-A1	3/30/2023		
127553-01401	IW204P1	PROCESS FOR PREPARING SOLUBLE GUANYLATE CYCLASE STIMULATORS	United States of America	62/639642	3/7/2018				
127553-01420	IW204PCT1	PROCESS FOR PREPARING SOLUBLE GUANYLATE CYCLASE STIMULATORS	Patent Cooperation Treaty	PCT/US2019/021076	3/7/2019	WO 2019/173548	9/12/2019		
127553-01402	IW204PCT1US1	PROCESS FOR PREPARING SOLUBLE GUANYLATE CYCLASE STIMULATORS	United States of America	16/976249	8/27/2020	US-2021-0032254-A1	2/4/2021	11466014	10/11/2022
127553-01403	IW204PCT1US1CON1	PROCESS FOR PREPARING SOLUBLE GUANYLATE CYCLASE STIMULATORS	United States of America	17/954725	9/28/2022				

		GUANYLATE CYCLASE STIMULATORS						
127553-05401	IW208P1	USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS	United States of America	62/696582	7/11/2018			
127553-05402	IW208P2	USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS	United States of America	62/697671	7/13/2018			
127553-05420	IW208PCT1	USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS	Patent Cooperation Treaty	PCT/US2019/041437	7/11/2019	WO2020/014504	1/16/2020	
127553-05403	IW208PCT1US1	USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS	United States of America	17/258913	1/8/2021	US-2021- 0177846-A1	6/17/2021	

PATENT

REEL: 064889 FRAME: 0473

RECORDED: 09/13/2023